ANKE BIO(SZ:300009) Zheng Quan Shi Bao Wang·2025-08-25 11:52Core Viewpoint - Anke Bio has received approval for its long-acting recombinant human follicle-stimulating hormone (FSH-CTP) injection, marking it as the first of its kind in China, which is expected to enhance the company's market position and revenue potential [1][2] Group 1: Product Approval and Market Impact - The FSH-CTP injection, branded as Shengnuo, is the first long-acting recombinant FSH approved in China, providing a significant market advantage due to the lack of similar competing products [1][2] - The product is designed for controlled ovarian stimulation (COS) in assisted reproductive technology, showing comparable clinical outcomes to short-acting FSH while reducing the frequency of injections, thus improving patient convenience and compliance [1] Group 2: Company Strategy and Future Outlook - Anke Bio aims to enhance its product pipeline and market competitiveness through the exclusive agency agreement for FSH-CTP, which is expected to contribute to revenue growth [2] - The company has prepared its sales team for the commercial launch of FSH-CTP, anticipating that the product will become a new profit growth point as market demand increases [2]